CO2020001740A2 - Agentes de iarn y composiciones para inhibir la expresión de la angiopoyetina tipo 3 (angptl3) y métodos de uso - Google Patents
Agentes de iarn y composiciones para inhibir la expresión de la angiopoyetina tipo 3 (angptl3) y métodos de usoInfo
- Publication number
- CO2020001740A2 CO2020001740A2 CONC2020/0001740A CO2020001740A CO2020001740A2 CO 2020001740 A2 CO2020001740 A2 CO 2020001740A2 CO 2020001740 A CO2020001740 A CO 2020001740A CO 2020001740 A2 CO2020001740 A2 CO 2020001740A2
- Authority
- CO
- Colombia
- Prior art keywords
- angptl3
- agents
- compositions
- irna agents
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/332—Abasic residue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente divulgación se refiere a agentes de iARN, por ejemplo, agentes de iARN de cadena doble, capaces de inhibir la expresión del gen de la Angiopoyetina tipo 3 (también denominada ANGPTL3, ANGPL3, proteína angiopoyetina tipo 3), y composiciones que incluyen agentes de iARN de ANGPTL3. También se divulgan métodos para usar los agentes de iARN de ANGPTL3 y composiciones. Los agentes de iARN de ANGPTL3 divulgados en la presente pueden estar conjugados con ligandos de direccionamiento para facilitar la administración a células, inclusive a hepatocitos. También se describen composiciones farmacéuticas que incluyen uno o más agentes de iARN de ANGPTL3, opcionalmente con uno o más productos terapéuticos adicionales. La administración de los agentes de iARN de ANGPTL3 in vivo proporciona la inhibición de la expresión del gen ANGPTL3, y puede dar como resultado niveles de triglicéridos y/o niveles de colesterol reducidos en el sujeto. Los agentes de iARN se pueden usar en métodos de tratamiento de enfermedades y trastornos relacionados con ANGPTL3 que incluyen enfermedades cardiovasculares, tales como hipertrigliceridemia e hiperlipidemia
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762558819P | 2017-09-14 | 2017-09-14 | |
US201762583919P | 2017-11-09 | 2017-11-09 | |
US201862651284P | 2018-04-02 | 2018-04-02 | |
US201862694976P | 2018-07-07 | 2018-07-07 | |
PCT/US2018/050848 WO2019055633A1 (en) | 2017-09-14 | 2018-09-13 | RNAI AGENTS AND COMPOSITIONS FOR INHIBITING ANALOGUE EXPRESSION OF ANGIOPOIETIN 3 (ANGPTL3) AND METHODS OF USE |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2020001740A2 true CO2020001740A2 (es) | 2020-05-29 |
Family
ID=65630620
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2020/0001740A CO2020001740A2 (es) | 2017-09-14 | 2020-02-14 | Agentes de iarn y composiciones para inhibir la expresión de la angiopoyetina tipo 3 (angptl3) y métodos de uso |
Country Status (22)
Country | Link |
---|---|
US (2) | US10995335B2 (es) |
EP (1) | EP3681513A4 (es) |
JP (2) | JP7281452B2 (es) |
KR (1) | KR20200044837A (es) |
CN (2) | CN111343994B (es) |
AU (1) | AU2018331383A1 (es) |
BR (1) | BR112020003126A2 (es) |
CA (1) | CA3074320A1 (es) |
CL (1) | CL2020000666A1 (es) |
CO (1) | CO2020001740A2 (es) |
EC (1) | ECSP20018305A (es) |
IL (1) | IL273173A (es) |
JO (1) | JOP20200050A1 (es) |
MX (1) | MX2020001912A (es) |
PE (1) | PE20201287A1 (es) |
PH (1) | PH12020500309A1 (es) |
SG (1) | SG11201912188RA (es) |
TN (1) | TN2020000038A1 (es) |
TW (1) | TWI823866B (es) |
UY (1) | UY37881A (es) |
WO (1) | WO2019055633A1 (es) |
ZA (1) | ZA202103669B (es) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112961855A (zh) | 2011-06-21 | 2021-06-15 | 阿尔尼拉姆医药品有限公司 | 血管生成素样3(ANGPTL3)iRNA组合物及其使用方法 |
SG11201901841TA (en) * | 2016-09-02 | 2019-03-28 | Arrowhead Pharmaceuticals Inc | Targeting ligands |
FI3607069T3 (fi) | 2017-04-05 | 2023-01-13 | Tuotteita ja koostumuksia | |
EP4013870A1 (en) | 2019-08-13 | 2022-06-22 | Alnylam Pharmaceuticals, Inc. | Small ribosomal protein subunit 25 (rps25) irna agent compositions and methods of use thereof |
WO2021087036A1 (en) | 2019-11-01 | 2021-05-06 | Alnylam Pharmaceuticals, Inc. | HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
TW202132568A (zh) | 2019-11-13 | 2021-09-01 | 美商阿尼拉製藥公司 | 用於治療血管收縮素原相關病症之方法及組成物 |
IL293824A (en) | 2019-12-13 | 2022-08-01 | Alnylam Pharmaceuticals Inc | Compositions of RNA material (c9orf72) human chromosome 9 open reading frame 72 and methods of using them |
TW202138559A (zh) | 2019-12-16 | 2021-10-16 | 美商阿尼拉製藥公司 | 含類PATATIN磷脂酶結構域3(PNPLA3)iRNA組成物及其使用方法 |
WO2021167841A1 (en) | 2020-02-18 | 2021-08-26 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof |
EP4114947A1 (en) | 2020-03-05 | 2023-01-11 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases |
EP4114948A1 (en) | 2020-03-06 | 2023-01-11 | Alnylam Pharmaceuticals, Inc. | Ketohexokinase (khk) irna compositions and methods of use thereof |
CA3172117A1 (en) * | 2020-03-18 | 2021-09-23 | Bob D. Brown | Compositions and methods for inhibiting angptl3 expression |
EP4121534A1 (en) | 2020-03-18 | 2023-01-25 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant |
EP4127168A1 (en) | 2020-03-26 | 2023-02-08 | Alnylam Pharmaceuticals, Inc. | Coronavirus irna compositions and methods of use thereof |
KR20220158011A (ko) * | 2020-03-26 | 2022-11-29 | 애로우헤드 파마슈티컬스 인코포레이티드 | PNPLA3의 발현을 억제하기 위한 RNAi 작용제, 이의 약제학적 조성물, 및 사용 방법 |
WO2021206922A1 (en) | 2020-04-07 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof |
EP4133076A1 (en) | 2020-04-07 | 2023-02-15 | Alnylam Pharmaceuticals, Inc. | Angiotensin-converting enzyme 2 (ace2) irna compositions and methods of use thereof |
CA3181400A1 (en) | 2020-04-27 | 2021-11-04 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein e (apoe) irna agent compositions and methods of use thereof |
IL297680A (en) | 2020-04-30 | 2022-12-01 | Alnylam Pharmaceuticals Inc | IRNA compounds complement factor b (cfb) and methods of using them |
WO2021252557A1 (en) | 2020-06-09 | 2021-12-16 | Alnylam Pharmaceuticals, Inc. | Rnai compositions and methods of use thereof for delivery by inhalation |
TW202214856A (zh) | 2020-06-18 | 2022-04-16 | 美商阿尼拉製藥公司 | 黃嘌呤脫氫酶(XDH)iRNA組成物及其使用之方法 |
EP4217489A1 (en) | 2020-09-24 | 2023-08-02 | Alnylam Pharmaceuticals, Inc. | Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof |
WO2022068923A1 (zh) * | 2020-09-30 | 2022-04-07 | 纳肽得(青岛)生物医药有限公司 | 血管生成素样3(ANGPTL3)的siRNA及其用途 |
JP2023544413A (ja) | 2020-10-05 | 2023-10-23 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | Gタンパク質共役受容体75(GPR75)iRNA組成物およびその使用方法 |
WO2022079222A1 (en) * | 2020-10-16 | 2022-04-21 | Sanofi | Novel rna compositions and methods for inhibiting angptl3 |
EP4232582A1 (en) | 2020-10-23 | 2023-08-30 | Alnylam Pharmaceuticals, Inc. | Mucin 5b (muc5b) irna compositions and methods of use thereof |
JP2023549500A (ja) | 2020-11-13 | 2023-11-27 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | 凝固第V因子(F5)iRNA組成物およびその使用方法 |
EP4259795A1 (en) | 2020-12-08 | 2023-10-18 | Alnylam Pharmaceuticals, Inc. | Coagulation factor x (f10) irna compositions and methods of use thereof |
WO2022150260A1 (en) | 2021-01-05 | 2022-07-14 | Alnylam Pharmaceuticals, Inc. | COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
BR112023015761A2 (pt) | 2021-02-12 | 2023-11-07 | Alnylam Pharmaceuticals Inc | Superóxido dismutase 1 (sod1) composições de irna e métodos de uso das mesmas para tratar ou prevenir doenças neurodegenerativas associadas a superóxido dismutase 1 (sod1) |
JP2024509783A (ja) | 2021-02-25 | 2024-03-05 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | プリオンタンパク質(prnp)irna組成物およびその使用方法 |
CA3211059A1 (en) | 2021-02-26 | 2022-09-01 | Alnylam Pharmaceuticals, Inc. | Ketohexokinase (khk) irna compositions and methods of use thereof |
WO2022187435A1 (en) | 2021-03-04 | 2022-09-09 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof |
EP4305169A1 (en) | 2021-03-12 | 2024-01-17 | Alnylam Pharmaceuticals, Inc. | Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof |
CN117203336A (zh) | 2021-03-29 | 2023-12-08 | 阿尔尼拉姆医药品有限公司 | 亨廷顿蛋白(HTT)iRNA药剂组合物以及其使用方法 |
WO2022212153A1 (en) | 2021-04-01 | 2022-10-06 | Alnylam Pharmaceuticals, Inc. | Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof |
JP2024517686A (ja) | 2021-04-26 | 2024-04-23 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | 膜貫通プロテアーゼ、セリン6(TMPRSS6)iRNA組成物およびその使用方法 |
EP4330396A1 (en) | 2021-04-29 | 2024-03-06 | Alnylam Pharmaceuticals, Inc. | Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof |
WO2022245583A1 (en) | 2021-05-18 | 2022-11-24 | Alnylam Pharmaceuticals, Inc. | Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof |
EP4347823A1 (en) | 2021-06-02 | 2024-04-10 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
AU2022283796A1 (en) | 2021-06-04 | 2023-11-09 | Alnylam Pharmaceuticals, Inc. | HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
JP2024523000A (ja) | 2021-06-08 | 2024-06-25 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | シュタルガルト病及び/又は網膜結合タンパク質4(rbp4)関連障害を治療又は予防するための組成物及び方法 |
IL309296A (en) | 2021-06-30 | 2024-02-01 | Alnylam Pharmaceuticals Inc | Methods and compositions for the treatment of angiotensinogen-related disorder (AGT-) |
TW202333748A (zh) | 2021-07-19 | 2023-09-01 | 美商艾拉倫製藥股份有限公司 | 用於處置具有或有風險發展非原發性高草酸鹽尿疾病或病症的個體的方法及組成物 |
WO2023003922A1 (en) | 2021-07-21 | 2023-01-26 | Alnylam Pharmaceuticals, Inc. | Metabolic disorder-associated target gene irna compositions and methods of use thereof |
TW202325312A (zh) | 2021-07-23 | 2023-07-01 | 美商艾拉倫製藥股份有限公司 | β-鏈蛋白(CTNNB1)iRNA組成物及其使用方法 |
EP4377458A1 (en) | 2021-07-29 | 2024-06-05 | Alnylam Pharmaceuticals, Inc. | 3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof |
EP4381067A1 (en) | 2021-08-03 | 2024-06-12 | Alnylam Pharmaceuticals, Inc. | Transthyretin (ttr) irna compositions and methods of use thereof |
EP4381071A1 (en) | 2021-08-04 | 2024-06-12 | Alnylam Pharmaceuticals, Inc. | Irna compositions and methods for silencing angiotensinogen (agt) |
IL310407A (en) | 2021-08-13 | 2024-03-01 | Alnylam Pharmaceuticals Inc | Factor XII (F12) IRNA compositions and methods of using them |
WO2023044370A2 (en) | 2021-09-17 | 2023-03-23 | Alnylam Pharmaceuticals, Inc. | Irna compositions and methods for silencing complement component 3 (c3) |
CA3232420A1 (en) | 2021-09-20 | 2023-03-23 | Alnylam Pharmaceuticals, Inc. | Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof |
IL310929A (en) * | 2021-09-23 | 2024-04-01 | Shanghai Argo Biopharmaceutical Co Ltd | Preparations and methods for inhibiting expression of angiopoietin-like protein 3 |
CA3234887A1 (en) | 2021-10-15 | 2023-04-20 | Alnylam Pharmaceuticals, Inc. | Extra-hepatic delivery irna compositions and methods of use thereof |
WO2023076450A2 (en) | 2021-10-29 | 2023-05-04 | Alnylam Pharmaceuticals, Inc. | HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
CN118302525A (zh) | 2021-10-29 | 2024-07-05 | 阿尔尼拉姆医药品有限公司 | 补体因子B(CFB)iRNA组合物及其使用方法 |
WO2023093896A1 (zh) * | 2021-11-29 | 2023-06-01 | 上海舶望制药有限公司 | 用于抑制乙型肝炎病毒(hbv)蛋白表达的组合物和方法 |
WO2023122656A1 (en) | 2021-12-22 | 2023-06-29 | Regeneron Pharmaceuticals, Inc. | Treatment of kidney diseases with angiopoietin like 3 (angptl3) inhibitors |
WO2023134705A1 (zh) * | 2022-01-11 | 2023-07-20 | 上海金中锘美生物医药科技有限公司 | 抑制angptl3表达的rna干扰剂及其用途 |
WO2023141314A2 (en) | 2022-01-24 | 2023-07-27 | Alnylam Pharmaceuticals, Inc. | Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof |
WO2023196941A1 (en) * | 2022-04-08 | 2023-10-12 | Arrowhead Pharmaceuticals, Inc. | Treatment of a non-alcoholic fatty liver disease |
CN116987696A (zh) * | 2022-08-04 | 2023-11-03 | 北京福元医药股份有限公司 | 用于抑制angptl3基因表达的双链核糖核酸及其修饰物、缀合物和用途 |
WO2024032608A1 (zh) * | 2022-08-08 | 2024-02-15 | 大睿生物医药科技(上海)有限公司 | 调控ANGPTL3基因活性的siRNA分子 |
WO2024039776A2 (en) | 2022-08-18 | 2024-02-22 | Alnylam Pharmaceuticals, Inc. | Universal non-targeting sirna compositions and methods of use thereof |
WO2024044542A2 (en) * | 2022-08-22 | 2024-02-29 | Arrowhead Pharmaceuticals, Inc. | Methods for the treatment of angptl3-related diseases and disorders |
WO2024102913A1 (en) | 2022-11-10 | 2024-05-16 | Regeneron Pharmaceuticals, Inc. | Treatment of kidney diseases with a combination of angiopoietin like 3 (angptl3) inhibitors and solute carrier family 5 member 2 (slc5a2) inhibitors |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
NL9201440A (nl) | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennaire clusterglycosiden, hun bereiding en toepassing. |
US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
MXPA01009073A (es) | 1999-03-10 | 2002-05-06 | Phogen Ltd | Suministro de acidos nucleicos y proteinas a las celulas. |
RU2002115295A (ru) | 1999-12-09 | 2004-01-10 | Санкио Компани, Лимитед (Jp) | Способ испытания терапевтического или профилактического средства от гиперлипидемии |
CN101905024A (zh) * | 2001-11-16 | 2010-12-08 | 杰南技术公司 | 含有血管生成素-样蛋白质3angptl3的组合物及其使用方法 |
CA2500224C (en) * | 2002-09-25 | 2015-04-28 | University Of Massachusetts | In vivo gene silencing by chemically modified and stable sirna |
WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
EP1560931B1 (en) | 2002-11-14 | 2011-07-27 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
US20040198640A1 (en) | 2003-04-02 | 2004-10-07 | Dharmacon, Inc. | Stabilized polynucleotides for use in RNA interference |
US20040224405A1 (en) | 2003-05-06 | 2004-11-11 | Dharmacon Inc. | siRNA induced systemic gene silencing in mammalian systems |
US20070276134A1 (en) * | 2006-05-24 | 2007-11-29 | Nastech Pharmaceutical Company Inc. | Compositions and methods for complexes of nucleic acids and organic cations |
CN101500548A (zh) | 2006-08-18 | 2009-08-05 | 弗·哈夫曼-拉罗切有限公司 | 用于体内递送多核苷酸的多缀合物 |
CA2910760C (en) | 2007-12-04 | 2019-07-09 | Muthiah Manoharan | Targeting lipids |
AU2010324658A1 (en) * | 2009-11-26 | 2012-05-03 | Quark Pharmaceuticals, Inc. | siRNA compounds comprising terminal substitutions |
JP5822845B2 (ja) * | 2010-01-08 | 2015-11-25 | アイシス ファーマシューティカルズ, インコーポレーテッド | アンジオポエチン様3発現の調節 |
EP3023495B1 (en) | 2010-02-24 | 2019-05-08 | Arrowhead Pharmaceuticals, Inc. | Compositions for targeted delivery of sirna |
WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
US8501930B2 (en) | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
CN112961855A (zh) * | 2011-06-21 | 2021-06-15 | 阿尔尼拉姆医药品有限公司 | 血管生成素样3(ANGPTL3)iRNA组合物及其使用方法 |
US8932572B2 (en) | 2011-08-26 | 2015-01-13 | Arrowhead Madison Inc. | Poly(vinyl ester) polymers for in vivo nucleic acid delivery |
US9796974B2 (en) * | 2011-11-18 | 2017-10-24 | Alnylam Pharmaceuticals, Inc. | Modified RNAi agents |
CN103764153A (zh) | 2012-04-18 | 2014-04-30 | 箭头研究公司 | 用于体内核酸递送的聚(丙烯酸酯)聚合物 |
EP2844261B1 (en) * | 2012-05-02 | 2018-10-17 | Sirna Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
PT3087183T (pt) * | 2013-12-24 | 2020-10-08 | Ionis Pharmaceuticals Inc | Modulação da expressão da proteína relacionada com angiopoietina 3 |
SI3137605T1 (sl) | 2014-05-01 | 2021-02-26 | Ionis Pharmaceuticals, Inc. | Sestavki in metode za modulacijo ekspresije angiopoetin 3-podobnega |
KR102494171B1 (ko) | 2014-08-20 | 2023-02-02 | 알닐람 파마슈티칼스 인코포레이티드 | 변형 이중-가닥 rna 제제 |
WO2016154127A2 (en) | 2015-03-20 | 2016-09-29 | Protiva Biotherapeutics, Inc. | Compositions and methods for treating hypertriglyceridemia |
AU2016247922B2 (en) * | 2015-04-13 | 2022-04-28 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof |
JOP20210043A1 (ar) * | 2015-10-01 | 2017-06-16 | Arrowhead Pharmaceuticals Inc | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa |
UY37146A (es) | 2016-03-07 | 2017-09-29 | Arrowhead Pharmaceuticals Inc | Ligandos de direccionamiento para compuestos terapéuticos |
MA45328A (fr) * | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
MA45340A (fr) * | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Acides nucléiques du récepteur des androgènes et leurs utilisations |
SG11201901841TA (en) | 2016-09-02 | 2019-03-28 | Arrowhead Pharmaceuticals Inc | Targeting ligands |
-
2018
- 2018-09-13 EP EP18855310.1A patent/EP3681513A4/en active Pending
- 2018-09-13 KR KR1020207007014A patent/KR20200044837A/ko not_active Application Discontinuation
- 2018-09-13 CN CN201880073901.XA patent/CN111343994B/zh active Active
- 2018-09-13 JP JP2020514926A patent/JP7281452B2/ja active Active
- 2018-09-13 WO PCT/US2018/050848 patent/WO2019055633A1/en active Application Filing
- 2018-09-13 BR BR112020003126-7A patent/BR112020003126A2/pt unknown
- 2018-09-13 CN CN202311448750.0A patent/CN117701562A/zh active Pending
- 2018-09-13 SG SG11201912188RA patent/SG11201912188RA/en unknown
- 2018-09-13 PE PE2020000671A patent/PE20201287A1/es unknown
- 2018-09-13 US US16/130,377 patent/US10995335B2/en active Active
- 2018-09-13 TN TNP/2020/000038A patent/TN2020000038A1/en unknown
- 2018-09-13 JO JOP/2020/0050A patent/JOP20200050A1/ar unknown
- 2018-09-13 MX MX2020001912A patent/MX2020001912A/es unknown
- 2018-09-13 CA CA3074320A patent/CA3074320A1/en active Pending
- 2018-09-13 AU AU2018331383A patent/AU2018331383A1/en active Pending
- 2018-09-14 UY UY0001037881A patent/UY37881A/es unknown
- 2018-09-14 TW TW107132397A patent/TWI823866B/zh active
-
2020
- 2020-02-11 PH PH12020500309A patent/PH12020500309A1/en unknown
- 2020-02-14 CO CONC2020/0001740A patent/CO2020001740A2/es unknown
- 2020-03-09 IL IL273173A patent/IL273173A/en unknown
- 2020-03-12 EC ECSENADI202018305A patent/ECSP20018305A/es unknown
- 2020-03-13 CL CL2020000666A patent/CL2020000666A1/es unknown
-
2021
- 2021-04-15 US US17/231,479 patent/US20210238602A1/en active Pending
- 2021-05-28 ZA ZA2021/03669A patent/ZA202103669B/en unknown
-
2023
- 2023-02-27 JP JP2023028733A patent/JP2023054368A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
TWI823866B (zh) | 2023-12-01 |
ECSP20018305A (es) | 2020-06-30 |
EP3681513A1 (en) | 2020-07-22 |
UY37881A (es) | 2019-03-29 |
KR20200044837A (ko) | 2020-04-29 |
PE20201287A1 (es) | 2020-11-24 |
CN111343994B (zh) | 2023-11-21 |
TN2020000038A1 (en) | 2021-10-04 |
US10995335B2 (en) | 2021-05-04 |
CN111343994A (zh) | 2020-06-26 |
PH12020500309A1 (en) | 2021-01-25 |
US20210238602A1 (en) | 2021-08-05 |
US20190078089A1 (en) | 2019-03-14 |
SG11201912188RA (en) | 2020-01-30 |
CA3074320A1 (en) | 2019-03-21 |
JOP20200050A1 (ar) | 2020-03-05 |
JP2020534268A (ja) | 2020-11-26 |
JP7281452B2 (ja) | 2023-05-25 |
EP3681513A4 (en) | 2021-09-22 |
CN117701562A (zh) | 2024-03-15 |
JP2023054368A (ja) | 2023-04-13 |
AU2018331383A1 (en) | 2020-04-23 |
MX2020001912A (es) | 2020-03-24 |
WO2019055633A1 (en) | 2019-03-21 |
CL2020000666A1 (es) | 2020-08-14 |
ZA202103669B (en) | 2023-03-29 |
IL273173A (en) | 2020-04-30 |
TW201922264A (zh) | 2019-06-16 |
BR112020003126A2 (pt) | 2020-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2020001740A2 (es) | Agentes de iarn y composiciones para inhibir la expresión de la angiopoyetina tipo 3 (angptl3) y métodos de uso | |
ECSP20017905A (es) | AGENTES DE iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DE LA APOLIPOPROTEÍNA C-III (APOC3) | |
CO2018003678A2 (es) | Composiciones y métodos para inhibir la expresión génica de lpa | |
CO2017004728A2 (es) | Composiciones y métodos para inhibir la expresión del gen hao1 (hidroxiácido-oxidasa 1 (glicolato-oxidasa) | |
CL2016003041A1 (es) | Ácidos ribonucleicos bicatenarios aislados, composiciones farmacéuticas que los comprenden y método para inhibir la expresión del gen alas1 basado en la administración de dicha composición. divisional de solicitud 2725-2014. | |
GT201500330A (es) | Composiciones y métodos de uso de interferencia de arn en serpina 1 | |
EA201692318A1 (ru) | Композиции и способы для ингибирования экспрессии гена альфа-1-антитрипсина | |
ECSP20000655A (es) | AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO | |
AR113254A1 (es) | AGENTES DE iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DE LA ANGIOPOYETINA TIPO 3 (ANGPTL3) Y MÉTODOS DE USO | |
AR113014A1 (es) | AGENTES DE iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DE LA APOLIPOPROTEÍNA C-III (APOC3) | |
AR106227A1 (es) | COMPOSICIONES Y MÉTODOS PARA INHIBIR LA EXPRESIÓN GÉNICA DEL GEN DE LA APOLIPOPROTEÍNA APO(a) (LPA) | |
AR113454A1 (es) | AGENTES iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DEL RECEPTOR DE ASIALOGLICOPROTEÍNA 1 | |
EA202090687A1 (ru) | РНКи-АГЕНТЫ И КОМПОЗИЦИИ ДЛЯ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ АПОЛИПОПРОТЕИНА C-III (APOC3) | |
AR112754A1 (es) | AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE a-ENaC Y MÉTODOS DE USO | |
CR20200117A (es) | Agentes de iarn y composiciones para inhibir la expresión de la angiopoyetina tipo 3 (angptl3) y métodos de uso | |
AR104542A1 (es) | COMPOSICIONES DE ARNi CONTRA FACTOR XII (FACTOR DE HAGEMAN) (F12), CALICREÍNA B, PLASMÁTICA (FACTOR DE FLETCHER) 1 (KLKB1), Y QUININÓGENO 1 (KNG1) Y MÉTODOS DE USO DE LOS MISMOS |